

REVIEW

Role of hydrogen sulphide in physiological and pathological angiogenesis

Yan-Xia Zhang^{1,2}  | Mi-Rong Jing^{1,2} | Chun-Bo Cai^{1,2} | Shuai-Gang Zhu^{1,2} |
Chao-Jing Zhang^{1,2} | Qi-Meng Wang^{1,2} | Yuan-Kun Zhai^{1,3} | Xin-Ying Ji^{1,2,4} |
Dong-Dong Wu^{1,2,3} 

¹Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China

²Kaifeng Municipal Key Laboratory of Cell Signal Transduction, Henan Provincial Engineering Centre for Tumor Molecular Medicine, Henan University, Kaifeng, Henan, China

³School of Stomatology, Henan University, Kaifeng, Henan, China

⁴Kaifeng Key Laboratory of Infection and Biological Safety, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, China

Correspondence

Yuan-Kun Zhai, Xin-Ying Ji, and Dong-Dong Wu, Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Email: zhaiyunkun@henu.edu.cn, 10190096@vip.henu.edu.cn, and ddwubiomed2010@163.com

Funding information

National Natural Science Foundation of China, Grant/Award Numbers: 81670088, 81802718; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China, Grant/Award Number: 2020GGJS038; Foundation of Science & Technology Department of Henan Province, China, Grant/Award Numbers: 222102310495, 222102310490

Abstract

The role of hydrogen sulphide (H₂S) in angiogenesis has been widely demonstrated. Vascular endothelial growth factor (VEGF) plays an important role in H₂S-induced angiogenesis. H₂S promotes angiogenesis by upregulating VEGF via pro-angiogenic signal transduction. The involved signalling pathways include the mitogen-activated protein kinase pathway, phosphoinositide-3 kinase pathway, nitric oxide (NO) synthase/NO pathway, signal transducer and activator of transcription 3 (STAT3) pathway, and adenosine triphosphate (ATP)-sensitive potassium (K_{ATP}) channels. H₂S has been shown to contribute to tumour angiogenesis, diabetic wound healing, angiogenesis in cardiac and cerebral ischaemic tissues, and physiological angiogenesis during the menstrual cycle and pregnancy. Furthermore, H₂S can exert an anti-angiogenic effect by inactivating Wnt/ β -catenin signalling or blocking the STAT3 pathway in tumours. Therefore, H₂S plays a double-edged sword role in the process of angiogenesis. The regulation of H₂S production is a promising therapeutic approach for angiogenesis-associated diseases. Novel H₂S donors and/or inhibitors can be developed in the treatment of angiogenesis-dependent diseases.

1 | INTRODUCTION

Angiogenesis refers to the physiological process of forming new blood vessels from existing capillaries or posterior veins of capillaries.^{1–4} Angiogenesis plays a key role in human health and disease.⁵ Physiological angiogenesis is beneficial to embryonic development, female physiological period, and wound healing. Pathological angiogenesis leads to the occurrence of a variety of

diseases. Excessive angiogenesis can lead to cancer, arthritis, psoriasis and blindness, obesity, asthma, atherosclerosis, and some infectious diseases.^{6,7} Insufficient growth or degeneration of blood vessels can cause myocardial hypoxia, cerebral hypoxia, stroke, hypertension, and osteoporosis.^{2,8} These diseases associated with abnormal angiogenesis are collectively referred to as “angiogenesis-dependent diseases”.⁷ In light of angiogenesis is involved in many physiological and pathological processes, more efforts should

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Cell Proliferation* published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.




FIGURE 1 The synthesis of intracellular H₂S. CBS, CSE, 3-MST/CAT are enzymes that catalyse the production of H₂S in cells. CAT, cysteine aminotransferase; 3-MST, 3-mercaptopyruvate sulphurtransferase; CSE, cystathionine γ -lyase; CBS, cystathionine β -synthase.

be paid to illuminate its occurrence, regulation, and potential therapeutic targets.

Hydrogen sulphide (H₂S) is a toxic gas with an odour of rotten eggs.^{9,10} It is the third endogenous gas signalling molecule after carbon monoxide and nitric oxide (NO).¹¹ H₂S plays an important role in a variety of physiological and pathological processes.^{12–14} Given many studies have focused on H₂S and angiogenesis, the underlying mechanisms are needed to be further investigated. In this article, we highlight the mechanisms of action of H₂S in physiological and pathological angiogenesis.

2 | PRODUCTION AND METABOLISM OF H₂S

In mammals, H₂S is mainly produced by cystathionine γ -lyase (CSE), cystathionine β -synthase (CBS), 3-mercaptopyruvate sulphurtransferase (3-MST), and cysteine aminotransferase (CAT)^{15–19} (Figure 1). CSE, CBS, and 3-MST have different tissue distribution and subcellular localization.¹² CBS is mainly located in the liver and the central nervous system.²⁰ CSE, a predominant source of H₂S in the cardiovascular system, is localized to cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, and brown perivascular adipose tissue.^{21–26} CSE is also expressed in the peripheral vascular system, such as aorta, pulmonary artery, portal vein, and mesenteric artery.²⁷ CBS and CSE are both pyridoxal-5'-phosphate (PLP)-dependent enzymes that produce H₂S using homocysteine (Hcy) and L-cysteine as substrates. As a non-PLP-dependent enzyme, 3-MST is mostly located in mitochondria and produces H₂S with CAT using 3-mercaptopyruvate (3-MP) as substrate.²⁸ In addition, the three enzymes can be found in the vascular endothelium.^{18,29,30} The lipophilic characteristics of H₂S and the localization advantage of H₂S-producing enzymes together determine that H₂S plays a vital role in regulating vasodilation, angiogenesis and anti-endothelial cell senescence.^{31–39}

Scavenging mechanism contributes to alleviate toxic effects of H₂S. H₂S can be oxidized in mitochondria by the sulphide quinone oxidoreductase system to form thiosulphates and sulphates, or

methyated in the cytoplasm by thiol-S-methyltransferase to form dimethyl sulphide and methanethiol.^{40,41} It can also be bound by methaemoglobin to produce Sul haemoglobin, which is excreted by spleen.⁴²

3 | THE ROLE OF H₂S IN TUMOUR ANGIOGENESIS

In normal tissues, angiogenesis is regulated by anti-angiogenic factors and pro-angiogenic factors to achieve a vascular resting state. A large amount of oxygen and nutrients are needed for tumour division and proliferation. When the tumour exceeds a certain volume, new blood vessels are formed to maintain it. Tumour angiogenesis is the result of increased pro-angiogenic factors or decreased anti-angiogenic factors and is a necessary condition for the growth and metastasis of tumour.^{43,44}

3.1 | Hypoxia, hypoxia-inducible factor 1, and H₂S

In solid tumours, hypoxia is caused by high oxygen consumption, nutritional deficiency, and accumulation of metabolites. Hypoxia is a typical feature of the tumour microenvironment and is an important reason for malignant transformation of tumours.⁴⁵ Hypoxia-inducible factor 1 (HIF-1) is the major factor regulating oxygen homeostasis, which exists in mammalian cells cultured under reduced O₂ tension. HIF-1 has a basic-loop-helix-Per-ARNT-Sim (PAS) heterodimer structure, consisting of two subunits, HIF-1 α and HIF-1 β .⁴⁶

Under normal O₂ tension, HIF-1 α and HIF-2 α are hydroxylated by prolyl hydroxylases (PHDs), then bound by the von Hippel Lindau (VHL), and eventually degraded by the ubiquitin-proteasome system.^{47–49} In the hypoxic environment of the tumour, HIF-1 α /HIF-2 α cannot be hydroxylated due to inactivation of PHDs.⁵⁰ Decreased binding of HIF α to VHL promotes the entry of HIF-1 α -HIF-1 β dimer into the nucleus. The proliferation and migration of tumour cells and tube formation can be promoted by activating the expression of vascular endothelial growth factor (VEGF) and other angiogenesis-related

genes.^{51,52} Therefore, the activation of HIF-1 is one of the key adaptive response mechanisms of tumours to cope with the hypoxic environment.⁵³

In addition to the regulation of the degradation of HIF-1 α by hydroxylases, the protein translation of HIF-1 α in hypoxia is worthy of attention. This process is mediated by the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 via RAS/-RAF/MEK/ERK kinase cascade and the PI3K-AKT-mTOR pathway.^{52,54,55}

The level of H₂S is increased under anoxic conditions.^{45,56,57} On the one hand, CSE is promoted by hypoxia to transfer to the mitochondria, where the amount of cysteine is about three times than that in cytoplasmic matrix. Subsequently, the expression of H₂S in mammals is upregulated via the metabolism of cysteine by CSE.^{58,59} In the mitochondrial matrix, the oxygenation state of the haeme group contained in CBS is the decisive factor for Lon protease to recognize and degrade CBS protein. However, in hypoxia, the deoxygenated haeme group in CBS cannot be recognized by Lon protease, resulting in the accumulation of CBS in mitochondria.⁶⁰ HIF-1 can also increase the expression of CBS in the cerebellum and the cerebral cortex.⁶¹ On the other hand, the oxidative metabolism of H₂S in mitochondria is inhibited.^{62,63} It has been reported that pro-angiogenic effects of H₂S are mediated by inhibiting mitochondrial electron transport and oxidative phosphorylation, which increases glycolysis and the production of adenosine triphosphate (ATP).⁶⁴ Therefore, H₂S can play a cytoprotective role as an oxygen sensor in hypoxia.

Under anoxic conditions, H₂S has a regulatory effect on HIF-1. It has been shown that the protein level and activity of HIF-1 can be increased by endogenous H₂S and hypoxia in *Caenorhabditis elegans*.⁶⁵ The EGL laying defective (EGL)-9 is responsible for the hydroxylation of HIF-1. A negative regulator of EGL-9, CYSL-1, is homologous to CBS, can promote H₂S-induced HIF-1 accumulation after hypoxia by interacting with the C-terminus of EGL-9.⁶⁶ The expression and stability of HIF-1 α can be enhanced by supplementing H₂S with diallyl disulphide (DADS).⁶⁷ Under anoxic conditions, H₂S can also stimulate the expression and activation of HIF-1 in a NO-dependent manner.⁶⁸ Similarly, the mRNA and protein levels of HIF-1 and VEGF are increased by treating brain capillary endothelial cells with sodium hydrosulphide (NaHS), and the binding activity of HIF-1 α is enhanced under anoxic conditions to promote angiogenesis.⁶⁹ The expression of HIF-1 α induced by NaHS is dependent on nuclear factor-E2-related factor 2.⁷⁰ However, the translation of HIF-1 α and the expression of HIF-1 can also be inhibited by H₂S under hypoxia by enhancing the phosphorylation of eIF2 α .⁷¹ In some cases, HIF-1 can be inhibited by many H₂S donors.⁷² In conclusion, the regulation of HIF-1 by H₂S plays an important role in angiogenesis.

3.2 | The pro-angiogenic effect of H₂S in cancer

More and more studies have shown that a variety of H₂S-producing enzymes are dysregulated in various cancers, and the role of H₂S in cancer has been extensively studied.^{73,74}

Mechanistically, under hypoxic conditions, H₂S induces the proliferation and migration of endothelial cells (ECs) and promotes tumour angiogenesis by increasing the expression of HIF-1 α and VEGF.⁶⁹ It has been shown that H₂S can enhance the activity and translation of HIF-1 α . In non-small cell lung cancer, HIF-1 α is activated by H₂S via the PI3K-AKT pathway to regulate the epithelial-mesenchymal transition and angiogenesis.⁷⁵ H₂S promotes angiogenesis by downregulating miR-640 expression and increasing HIF-1 α levels via the VEGFR2-mTOR pathway.⁷⁶ In addition to increasing the source of HIF-1 α , inhibiting its degradation can also promote angiogenesis. For example, the degradation of HIF-1 α is blocked by pseudo hypoxia because of the lack of VHL in clear cell renal cell carcinoma, the level of H₂S is increased, which in turn will promote angiogenesis.⁷⁷ H₂S produced by CBS stimulates angiogenesis by activating AP-1 to upregulate VEGF in colon cancer.^{78,79} CSE can also promote angiogenesis through the VEGF signalling pathway, which is the key to the metastasis of breast cancer.⁸⁰ 3-MST has a promoting effect on the migration of vascular ECs cultured in a hypoxic environment.⁸¹ The intracellular calcium signal is induced by VEGF, resulting in the increase of intracellular Ca²⁺ concentration and promotion of ECs proliferation and migration. Therefore, H₂S plays an important role in promoting angiogenesis in cancer cells, which can be inhibited by DL-propargylglycine (PAG), a CSE inhibitor.⁸²⁻⁸⁴


H₂S-induced tumour angiogenesis also involves many other signalling pathways. It has been demonstrated that H₂S can promote angiogenesis in hepatocellular carcinoma (HCC), glioma, and oesophageal cancer by activating the nuclear factor-kappa B (NF- κ B), p38 mitogen-activated protein kinase (MAPK)/ERK1/2-COX-2 and HSP90 pathways, respectively.⁸⁵⁻⁸⁷ The similar effects have been observed in liver cancer and oesophageal cancer via the signal transducer and activator of transcription 3 (STAT3)-COX-2 and JAK2/STAT3 pathway.^{88,89} (Figure 2).

Given the pro-angiogenic effect of H₂S, tumours can be treated by antagonizing this effect. In the presence of non-organ-specific cancer prevention molecule, Korean red ginseng (KRGE), the expression levels of CSE and CBS in human umbilical cord blood endothelial cells (HUVECs) are effectively decreased. In addition, the expressions of HIF-1 α and VEGF are significantly reduced, indicating that the antagonism of H₂S-induced angiogenesis is the potential mechanism for KRGE to prevent gastric cancer.⁹⁰ The combination of traditional Chinese medicine kelp and curcuma zedoary can inhibit the production of endogenous H₂S, and the proliferation and metastasis of liver cancer cells are attenuated by downregulating the expression levels of the p-STAT3/BCL-2 and VEGF pathways and their downstream key genes p-ERK1/2 and p-AKT, indicating that H₂S plays a key role in the treatment of liver cancer.⁹¹ In conclusion, H₂S can act as a promising target of anti-angiogenic strategy in cancer treatment.

3.3 | The anti-angiogenic effect of H₂S in cancer

However, it should be noted that angiogenesis can also be inhibited by GYY4137, a donor of H₂S, which can reduce VEGF and

(A)



(B)




FIGURE 2 The pro-angiogenic and anti-angiogenic roles of H₂S in cancer progression. (A) Tumour angiogenesis is promoted by H₂S via stimulating AP-1, HIF-1α, PI3K, NF-κB, JAK2, MAPK and HSP90. (B) H₂S donors exert anti-angiogenic effect on the development of cancer. AKT, protein kinase B; AP-1, activating protein-1; Bcl-2, B-cell lymphoma 2; CD31, platelet/endothelial cell adhesion molecule-1; COX-2: cyclooxygenase-2; DADS, diallyl disulphide; DAS, diallyl sulphide; DATS, diallyl trisulphide; ERK, extracellular signal-related kinases; GM-CSF, granulocyte macrophage colony-stimulating factor; HIF-1α, hypoxia-inducible factor-1α; HSP90, heat-shock protein 90; IL-1β, interleukin-1β; IL-2, interleukin-2; IL-6, interleukin-6; IL-16, interleukin-16; JAK-2: janus kinase 2; MAPK, mitogen-activated protein kinase; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-kappa B; PI3K, phosphoinositide 3-kinase; S₂O₃²⁻, thiosulfate; STAT3, signal transducer and activator of transcription 3; TIMP, tissue inhibitor of metalloproteinase; TNF-α, tumour necrosis factor-α; VEGF, vascular endothelial growth factor; VEGF, vascular endothelial growth factor.

HIF-1α by blocking the STAT3 pathway in human HCC cells.⁹² In addition, the sustained-release H₂S donor, thiosulphate, can reduce the expression of VEGF-induced CSE and attenuate the proliferation of HUVECs, which plays a therapeutic role in anti-angiogenesis.⁹³

Garlic extracts, such as DADS, diallyl sulphide (DAS), and diallyl trisulphide (DATS), are widely used as H₂S donors, and their anti-angiogenic effects have been applied to cancer treatment.⁹³ In Ehrlich ascites tumour-bearing mice, DAS can inhibit angiogenesis in a dose-dependent manner.^{94,95} DADS acts as an inhibitor of angiogenesis by inhibiting the activation of matrix metalloproteinases during endothelial morphogenesis.⁹⁶ The novel pro-angiogenic effect of H₂S is dependent on AKT phosphorylation.⁹⁷ DATS has been extensively studied as an anti-cancer and chemopreventive agent.^{98–100} Angiogenesis could be inhibited by DATS via inactivating AKT and downregulating VEGF and VEGFR2 in HUVECs, reducing the activation of AKT and NF-κB in prostate cancer, inactivating the Wnt/β-catenin signal transduction in glioma, and reducing the synthesis of HIF-1α in breast cancer.^{72,101–104} (Figure 2).

In conclusion, H₂S has the dual effects of pro-angiogenesis and anti-angiogenesis. We speculate that the effect of H₂S on tumour angiogenesis follows a bell-shaped dose response, which may be regulated by the concentration of H₂S. At low concentrations, H₂S exhibits a protective role in promoting angiogenesis, while at high concentrations, it is opposite. It has been shown that NaHS acts as a double-edged sword in human HCC cells through the PTEN/AKT and the EGFR/ERK/MMP-2 signalling pathway. Angiogenesis is promoted by 25–100 μM NaHS, while 800–1000 μM NaHS shows opposite effect.¹⁰⁵

4 | THE ROLE OF H₂S IN ANGIOGENESIS IN CARDIOVASCULAR DISEASES

Numerous studies have shown that H₂S is an effective cardiovascular protective agent, which plays a role in promoting cardiovascular homeostasis and health through vasodilation, angiogenesis, inflammation, oxidative stress, and apoptosis.^{27,41,106,107} As an endogenous gas

stimulator of angiogenesis, H₂S has the effect of promoting angiogenesis in cardiovascular diseases such as ischaemic diseases, myocardial infarction, heart failure and atherosclerosis.^{29,108}

4.1 | Interaction between H₂S and VEGF

The interaction between H₂S and VEGF can promote angiogenesis. CSE expression is enhanced in a calcium-dependent manner via VEGF-VEGFR2 binding, thus increasing H₂S levels.¹⁰⁹ In turn, VEGFR2 is activated by H₂S and the VEGF-VEGFR2 binding is enhanced by breaking the Cys1045-Cys1024 disulphide bond of VEGFR2.¹¹⁰

As a therapeutic target, angiogenesis plays an irreplaceable role in the recovery of ischaemic diseases.^{6,111} NaHS can promote the growth of collateral vessels, increase regional tissue blood flow in a rat with unilateral hindlimb ischaemia. These effects may be mediated by the interaction of upregulated VEGF in skeletal muscle cells, VEGFR2 in vascular endothelial cells, as well as the downstream signal transduction element AKT.^{37,112} S-propargyl-cysteine (SPRC), a novel water-soluble regulator, can enhance the interaction between VEGFR2 and growth factor receptor-bound protein 2 by activating CSE to produce endogenous H₂S. The phosphorylation level of STAT3 is induced. STAT3 moves from the cytoplasmic matrix to the nucleus via the JAK-STAT3 pathway, activates VEGF promoter, and promotes cell proliferation, migration and tube formation. Pathologically, after ligation of the coronary artery or the left femoral artery, treatment with SPRC can promote angiogenesis and alleviate ischaemia.¹¹³ In cerebral ischaemic diseases, cerebral ischaemia can be improved by H₂S via promoting the phosphorylation of AKT and ERK, as well as increasing the expression of VEGF and angiopoietin-1 (Ang-1).¹¹⁴ Therefore, H₂S can promote angiogenesis in ischaemic diseases via the AKT or JAK2-STAT3 pathway, which is mediated by VEGFR2.

4.2 | Interaction between H₂S and NO

In the cardiovascular and cerebrovascular system, H₂S and NO can interact and depend on each other to regulate angiogenesis.^{115–120} During tissue ischaemia, H₂S can increase the phosphorylation level of endothelial nitric oxide synthase (eNOS) at its activating site S1177 via the PI3K/AKT-dependent pathway.^{115,116} ATP-sensitive potassium channels mediate partial vascular functions of H₂S and participate in the activation of AKT.^{121,122} The production of NO is increased in ECs and vascular tissues via eNOS or xanthine oxidase-mediated nitrite reduction mechanism.⁶⁸ Soluble guanylate cyclase is bonded and activated by NO, which can catalyse guanosine triphosphate into cyclic guanosine monophosphate (cGMP).¹²³ H₂S can also increase cGMP by inhibiting the activity of phosphodiesterase.¹²⁴ The cGMP-dependent protein kinase G (PKG) is activated, which could contribute to the proliferation and migration of ECs or the expression of growth factors and angiogenesis through the downstream MAPK pathway.^{125–128} In addition to the cGMP/PKG/MAPK pathway, NO

also modulates HIF-1 α and VEGF-dependent angiogenesis, thus stimulating ischaemic vascular remodelling^{68,129} (Figure 3).

4.3 | H₂S in ischaemic diseases

H₂S has shown the protective role in limb ischaemic diseases by regulating angiogenesis. Under physiological conditions, a novel H₂S-NO hybrid molecule, ZYZ-803, could stimulate the expression of CSE and enhance the activity of endothelial eNOS. NO and H₂S are slowly released and mediate the increase of angiogenesis in rat aortic rings and mouse ischaemic hindlimb models via the SIRT1/VEGF/cGMP pathway.^{130,131} ZYZ-803 can also promote angiogenesis in mice with femoral artery ligation via the STAT3/Ca²⁺/CaM-dependent protein kinase II pathway.¹³² Similar to ZYZ-803, H₂S prodrug SG-1002 can promote angiogenesis in a porcine model of acute limb ischaemia and improve peripheral arterial disease by increasing the signal transduction of H₂S and NO in the circulation.¹³³ DATS can enhance ischaemia-induced angiogenesis and stimulate the phosphorylation of AKT and eNOS through the AKT-eNOS signalling pathway in mice with unilateral hindlimb ischaemia (HLI).¹³⁴ Another study has shown that the intramuscular injection of a poly (D,L-lactic-co-glycolic acid) microparticle system that contains DATS can promote therapeutic angiogenesis and prevent apoptosis and tissue necrosis in a mouse model of limb ischaemia.¹³⁵ Taken together, in limb ischaemic diseases, H₂S can mediate angiogenesis by activating the eNOS/NO pathway.

4.4 | H₂S in heart diseases

H₂S also has protective effect on myocardial ischaemia, myocardial infarction, and heart failure via angiogenesis.^{136,137} Myocardial ischaemia is usually caused by insufficient blood supply to the myocardium because of coronary stenosis. GYY4137, a slow-releasing H₂S donor, can attenuate adverse remodelling and promote angiogenesis after ischaemia.¹³⁸

VEGFR1 and VEGFR2, two receptor tyrosine kinases, can bind VEGF with high affinity, stimulate ECs proliferation, and enhance angiogenesis. Treatment with H₂S improves the cardiac function by increasing the expressions of VEGF, VEGFR1, and VEGFR2 but decreasing the levels of anti-angiogenic factors such as angiostatin and endostatin.^{139–143} The downregulation of CBS, CSE, and 5-methylenetetrahydrofolate reductase caused by myocardial infarction will result in hyperhomocysteinemia (HHcy) and inhibit ECs proliferation, migration and angiogenesis.^{144–146} HHcy can also inhibit angiogenesis by antagonizing the angiogenic signalling pathway of PPAR- γ /VEGF axis, which can be improved by GYY4137 via enhancing PPAR- γ -VEGF-eNOS-NO signal transduction in skeletal muscle cells.¹⁴⁷ It has been shown that GYY4137 can also promote cerebral angiogenesis in zebrafish through the eNOS/NO pathway.¹⁴⁸ In addition, HHcy is an independent risk factor for atherosclerosis with the typical feature of endothelial dysfunction. CSE is expressed in the




FIGURE 3 H₂S and NO interact and depend on each other to jointly regulate angiogenesis. AKT, protein kinase B; cGMP, cyclic guanosine monophosphate; CSE, cystathionine γ -lyase; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-related kinases; GTP, guanosine triphosphate; sGC, soluble guanylate cyclase; SIRT1, sirtuin 1; PDE, phosphodiesterase; PI3K, phosphoinositide 3-kinase; PKG, protein kinase G; VEGF, vascular endothelial growth factor.

microvessels of human atherosclerotic plaques and participates in micro-angiogenesis, which can improve endothelial function.^{149–151} In the renal vasculature, the disturbance of Hcy metabolism will lead to renovascular hypertension, which can be improved by the conversion of Hcy to H₂S via the AKT/FoxO3 pathway after gene therapy with CBS, CSE, and 3-MST.^{152,153}

Heart failure may be caused by myocardial infarction by upregulation of the levels of MMP-9 and anti-angiogenic factors.¹⁵⁴ Treatment with H₂S donors could inhibit the transition from compensatory hypertrophy to heart failure by inducing the production of MMP-2, inhibiting the expression of TIMP-3 and MMP-9, and promoting the synthesis of VEGF.¹⁵⁵ H₂S can attenuate cardiac dysfunction after heart failure via the VEGF-eNOS-NO pathway to promote angiogenesis and the GPx-1-HO-1 pathway to counteract oxidative stress.¹⁵⁶ HSD-R, a novel H₂S donor, can achieve myocardial protection by inhibiting local inflammation, reducing cardiomyocyte apoptosis, and promoting angiogenesis, indicating that HSD-R can act as a promising therapeutic agent for myocardial infarction and other ischaemic diseases.¹⁵⁷

In conclusion, in addition to its pro-angiogenic effect in myocardial infarction, H₂S can treat atherosclerosis and renovascular hypertension by improving HHcy-induced angiogenic disorders. H₂S also provides a clinical possibility for the prevention and treatment of heart failure by upregulating MMP2, downregulating MMP-9 and TIMP-3, and promoting angiogenesis through the eNOS-NO pathway.

5 | THE ROLE OF H₂S IN DIABETIC ANGIOGENESIS

Diabetes is a metabolic disease characterized by elevated blood glucose levels and is a main risk factor for vascular diseases. The vascular complications, mainly led by abnormal angiogenesis, can be divided into two types: macrovascular complications (coronary and peripheral arterial diseases, cerebrovascular) and microvascular complications (nephropathy, neuropathy, and retinopathy).¹⁵⁸

Refractory wound lesions are easily induced by abnormal angiogenesis in diabetic patients, and the basis of wound healing depends on angiogenesis.^{159–163} Impaired angiogenesis induced by diabetes is related to Ang-1/Tie 2 signalling.¹⁶⁴ The decreased expressions of many vascular growth factors such as platelet-derived growth factor

and VEGF are involved in the impaired angiogenesis caused by hyperglycaemia/diabetes.¹⁶⁵ H₂S promotes angiogenesis in diabetic db/db mice by increasing the expression levels of VEGF and Ang-1 in wound skin tissues and endothelial progenitor cells (EPCs).^{159,166} The similar effect has been observed by NaHS treatment in ob/ob mice.¹⁶⁷ Wound healing can be improved by NaHS in streptozotocin-induced diabetic rats, which is associated with enhanced angiogenesis and increased levels of intercellular adhesion molecule-1 (ICAM-1) and VEGF.¹⁶⁸ The occurrence of diabetic vascular complications is related to endothelial dysfunction, and angiogenesis is reduced by impaired function of ECs.^{169,170} In Type 2 diabetes, H₂S improves wound healing by restoring the function of EPCs and activating Ang-1.¹⁵⁹ H₂S plays a key role in maintaining the function of ECs and angiogenesis in diabetes.¹⁷¹ EC-related angiogenic property is stimulated by H₂S via the K_{ATP} channel/MAPK pathway.²⁹ H₂S can protect HUVECs against high glucose-induced injury. On the one hand, H₂S upregulates the miR-126-3p level and recovers ECs migration via downregulating the DNMT1 protein level induced by high glucose, thereby improving the impaired angiogenesis induced by high glucose.^{172,173} On the other hand, the activation of PI3K/AKT/eNOS pathway is essential for H₂S to prevent HUVECs from injury.¹⁷⁴ Accordingly, H₂S-releasing micelles are prepared to enhance HUVECs migration and tube formation by delivering H₂S.¹⁷⁵ The downregulation of CSE/H₂S system is related to diabetes-impaired angiogenesis. The activation of local CSE-H₂S-VEGF axis may contribute to pro-angiogenic effects of DH injection in diabetic hind limb ischaemia model mice.¹⁷⁶ Overexpression of CSE or treatment with DATS has therapeutic actions on diabetic mouse models by promoting revascularization in ischaemic tissue via eNOS/NO signalling pathway.^{177,178} Furthermore, impaired angiogenesis in hyperglycaemia/diabetes is associated with impaired pro-angiogenic properties of 3-MP. A 3-MST stimulator/cofactor, lipoic acid, can restore or improve the ability of 3-MP to stimulate angiogenesis and wound healing in hyperglycaemia.¹⁷⁹ Therefore, 3-MST pathway has the potential to promote angiogenesis.¹⁸⁰ These findings suggest that H₂S can improve angiogenesis in diabetes.

H₂S donors have shown angiogenic response in diabetic models. Islet transplantation into subcutaneous polymer scaffolds has been proved to be able to induce normoglycaemia in type 1 diabetes models. The fast-releasing H₂S donor, NaHS (25 or 50 μ mol/kg),

TABLE 1 The pro-angiogenic and anti-angiogenic roles of H₂S in various diseases.

Diseases		Mechanisms	Effects	References
Cancer	Non-small cell lung cancer	Activation of HIF-1 α by the PI3K-AKT pathway	Pro-angiogenesis	75
	Clear cell renal cell carcinoma	Blocking the degradation of HIF-1, elevating the level of H ₂ S		77
	Colon cancer	Up-regulating VEGF by activating AP-1		78,79
	Breast cancer	Through the VEGF signalling pathway		80
	Hepatocellular carcinoma	Activating NF- κ B and STAT3-COX-2 signalling pathways		85,88
	Glioma	Activating the p38 MAPK/ERK1/2-COX-2 pathway		86
	Oesophageal cancer	Activating HSP90 pathway and JAK2/STAT3 signalling pathway		87,89
Cardiovascular diseases	Limb ischaemia	Activating VEGF via JAK-STAT3 pathway; promoting angiogenesis through the SIRT1/VEGF/cGMP pathway, the STAT3/Ca ²⁺ /CaMKII pathway or the AKT-eNOS signalling pathway		113,130–134
	Cerebral ischaemia	Increasing expression of VEGF and Ang-1 by promoting phosphorylation of AKT and ERK		114
	Myocardial ischaemia	Attenuating adverse remodelling		138
	Myocardial infarction	Increasing pro-angiogenic growth factors and decreasing anti-angiogenic growth factors		139–143
	Heart failure	Increasing MMP-2 and VEGF, inhibiting MMP-9 and TIMP3; By the VEGF-eNOS-NO pro-angiogenic pathway		155,156
	HHcy	Enhancing VEGF-eNOS-NO signal transduction; converting Hcy to H ₂ S via the AKT/FoxO3 pathway		152,153
Diabetes		Up-regulating Ang-1, VEGF, ICAM-1, miR-126-3p; Activating the K _{ATP} channel/MAPK pathway or the PI3K/AKT/eNOS pathway		29,159,166–168,172–174
Pre-eclampsia		Limiting sFlt-1 and sEng, increasing VEGF and PlGF		195,196
Cancer	Hepatocellular carcinoma	Blocking the STAT3 pathway and downregulating VEGF	Anti-angiogenesis	92
	Ehrlich ascites tumour	Up-regulating of IL-2 and TIMP, down-regulating of IL-1 β , IL-16, TNF- α , GM-CSF and VEGF		94,95
	Prostate cancer	Inhibiting the activation of AKT and NF- κ B		102,103
	Glioma	Inactivating the Wnt/ β -catenin signal transduction		104
	Breast cancer	Reducing the synthesis of HIF-1 α		72

Abbreviations: AP-1, activating protein-1; AKT, protein kinase B; CaMKII, CaM-dependent protein kinase II; cGMP, cyclic guanosine monophosphate; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; FoxO3, Fork-head Box O3; GM-CSF, granulocyte macrophage colony-stimulating factor; HIF-1 α , hypoxia-inducible factor-1 α ; ICAM-1, intercellular adhesion molecule-1; IL-1 β , interleukin-1 β ; IL-2, interleukin-2; IL-16, interleukin-16; JAK2, janus kinase 2; MAPK, mitogen-activated protein kinase; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; NF- κ B, nuclear factor-kappa B; NO, nitric oxide; PI3K, phosphoinositide 3-kinase; PlGF, placental growth factor; sEng, soluble endocrine hormone; sFlt-1, soluble FMS-like tyrosine kinase-1; SIRT1, sirtuin 1; STAT3, signal transducer and activator of transcription 3; TIMP, tissue inhibitor of metalloproteinase; TNF- α , tumour necrosis factor- α ; VEGF, vascular endothelial growth factor.

is intraperitoneally injected into the nude mice implanted with subcutaneous scaffolds. After 63 days, the mRNA expression of angiogenesis marker CD105 and the number of CD31 positive vessels are significantly higher than those in the control group, indicating that H₂S can promote vascularization of subcutaneous scaffolds.¹⁸¹ However, the release of H₂S by NaHS is fast and difficult to control, which is prone to cause cytotoxicity due to high local concentration. To

solve this problem, a microparticle system (NaHS@MPs) encapsulated NaHS has been designed. The system can continuously provide H₂S and promote the proliferation, migration of epidermis cells/ECs and angiogenesis by extending the activation of p38 and ERK1/2, thereby accelerating the wound healing in diabetic mice.¹⁸²

In summary, H₂S can upregulate VEGF, Ang-1, and ICAM-1, as well as accelerate cell proliferation, migration and tube formation by

activating the K_{ATP} channel/MAPK pathway and the PI3K/AKT/eNOS pathway, thereby improving wound healing and treating diabetic vascular complications.

6 | THE ROLE OF H_2S IN ANGIOGENESIS OF THE REPRODUCTIVE SYSTEM

Angiogenesis is a normal physiological phenomenon of endometrial regeneration during menstrual cycles and pregnancy, which is related to the elevated level of H_2S .¹⁸³ CSE and CBS are expressed in human intrauterine tissues.¹⁸⁴ During the menstrual cycle and pregnancy, the endometrial CBS- H_2S production is stimulated due to the increase of oestrogen level, which promotes human endometrial angiogenesis.¹⁸⁵ Endogenous H_2S is required for a healthy placental vasculature. Pregnancy could increase the level of H_2S in human uterine artery endothelial cells and stimulate the production of placental VEGF in placental trophoblasts, which is mediated by the MAPK3/1 and AKT1-NOS3 pathways.^{186–188} In maternal obesity, DATS has been used to increase the level of H_2S in serum and placenta of mice, which can promote placental angiogenesis by regulating lipid metabolism, reducing inflammation, and activating the PI3K/AKT pathway.¹⁸⁹

Abnormal placental angiogenesis is associated with pre-eclampsia.¹⁹⁰ Pre-eclampsia is a pregnancy-related vascular disease and is the leading cause of maternal and foetal morbidity and mortality. Before the onset of pre-eclampsia, the circulating levels of soluble endoglin (sEng) and soluble FMS-like tyrosine kinase-1 (sFlt-1) are increased, and then VEGF and placental growth factor are decreased, thus leading to pre-eclampsia.^{191–194} The plasma H_2S level in women with pre-eclampsia is reduced. After treatment with GYY4137, sFlt-1 and sEng are inhibited and the effect of PAG on foetal growth can be weakened.^{195,196} Taken together, the decrease of CSE activity is associated with the pathogenesis of pre-eclampsia.

In contrast to the female reproductive system, although H_2S plays an important role in various male sex organs such as the penis, prostate, and vas deferens, the role of H_2S in the angiogenesis in male reproductive system is still unclear and needs further exploration to provide therapeutic targets for the related diseases.¹⁹⁷

7 | CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS

Numerous studies have shown that H_2S plays an important role in the angiogenesis of ECs. In this review, we summarize the roles of H_2S in physiological and pathological angiogenesis (Table 1). In tumours, H_2S has a pro-angiogenic effect by activating HIF-1 via the RAS/RAF/MEK/ERK cascade and the PI3K-AKT-mTOR pathway. VEGF is a crucial factor in H_2S -induced angiogenesis. In cardiovascular system, in addition to the AKT and JAK-STAT3 pathway mediated by VEGFR2, H_2S can stimulate angiogenic activity by interacting with NO. H_2S has achieved good therapeutic effects in diabetic vascular complications

by activating K_{ATP} channel/MAPK or PI3K/AKT/eNOS pathway to upregulate pro-angiogenic factors. Although H_2S can inhibit angiogenesis by blocking the STAT3 pathway or inactivating the Wnt/ β -catenin cascade in tumours, the underlying mechanism needs to be further investigated.

Nowadays, the role of H_2S in angiogenesis is widely studied in experimental models, which has made notable achievements. For example, H_2S can promote cell proliferation, migration and tube formation. In addition, whether H_2S plays a certain role in the degradation of the vascular basement membrane and the activation of ECs need to be explored. It is yet unknown how H_2S can affect the metabolism of ECs to achieve the physiological balance of blood vessels. Whether H_2S participates in the quiescence or maturation of vessels also needs to be further investigated. In addition to the concentration of H_2S , what other factors affect the dual roles of H_2S in tumour angiogenesis may be a novel direction. The anti-angiogenic effect of H_2S is mainly studied using H_2S donors, and the mechanism is worth exploring. Whether the anti-angiogenic effect of H_2S can be reversed by inhibiting H_2S -producing enzymes remains unclear. The molecules that can affect angiogenesis by interacting with H_2S could be further identified.

In conclusion, recent studies have demonstrated the role of H_2S in angiogenesis. However, the underlying mechanism has been partially demonstrated and needs to be elucidated more systematically and completely. Pharmacological inhibition and silencing endogenous H_2S synthase have been used in the treatment of excessive angiogenesis-related diseases. Supplementation of substrates and overexpression of H_2S -producing enzymes contribute to wound healing and the improvement of ischaemic diseases. Therefore, the regulation of H_2S production is a potential therapeutic approach for angiogenesis-dependent diseases. Novel H_2S donors and/or inhibitors can be developed in the treatment of angiogenesis-associated diseases.

AUTHOR CONTRIBUTIONS

Conceptualization: Yuan-Kun Zhai, Xin-Ying Ji, and Dong-Dong Wu. *Data curation:* Yan-Xia Zhang, Mi-Rong Jing, Chun-Bo Cai, Shuai-Gang Zhu, Chao-Jing Zhang, and Qi-Meng Wang. *Funding acquisition:* Xin-Ying Ji and Dong-Dong Wu. *Writing-original draft:* Yan-Xia Zhang. *Visualization and supervision:* Yuan-Kun Zhai, Xin-Ying Ji, and Dong-Dong Wu. *Writing-review and editing:* Yan-Xia Zhang and Dong-Dong Wu.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802718, 81670088), the Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China (No. 2020GGJS038), and the Foundation of Science & Technology Department of Henan Province, China (Nos. 222102310490, 222102310495).

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Yan-Xia Zhang  <https://orcid.org/0000-0003-4413-3959>

Dong-Dong Wu  <https://orcid.org/0000-0001-6739-8437>

REFERENCES

- Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med*. 2000;6(4):389-395. doi:10.1038/74651
- Carmeliet P. Angiogenesis in life, disease and medicine. *Nature*. 2005;438(7070):932-936. doi:10.1038/nature04478
- Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. *Nat Rev Mol Cell Biol*. 2007;8(6):464-478. doi:10.1038/nrm2183
- Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. *Angiogenesis*. 2017;20(4):409-426. doi:10.1007/s10456-017-9562-9
- Carmeliet P. Angiogenesis in health and disease. *Nat Med*. 2003;9(6):653-660. doi:10.1038/nm0603-653
- Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. *Nature*. 2005;438(7070):967-974. doi:10.1038/nature04483
- Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov*. 2007;6(4):273-286. doi:10.1038/nrd2115
- Holwerda KM, Karumanchi SA, Lely AT. Hydrogen sulfide: role in vascular physiology and pathology. *Curr Opin Nephrol Hypertens*. 2015;24(2):170-176. doi:10.1097/mnh.0000000000000096
- Reiffenstein RJ, Hulbert WC, Roth SH. Toxicology of hydrogen sulfide. *Annu Rev Pharmacol Toxicol*. 1992;32:109-134. doi:10.1146/annurev.pa.32.040192.000545
- Ramazzini B. De morbis artificum diatriba [diseases of workers]. 1713. *Am J Public Health*. 2001;91(9):1380-1382. doi:10.2105/ajph.91.9.1380
- Wang R. Two's company, three's a crowd: can H₂S be the third endogenous gaseous transmitter? *FASEB J*. 2002;16(13):1792-1798. doi:10.1096/fj.02-0211hyp
- Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev*. 2012;92(2):791-896. doi:10.1152/physrev.00017.2011
- Kimura H. Hydrogen sulfide and polysulfides as signaling molecules. *Proc Jpn Acad Ser B Phys Biol Sci*. 2015;91(4):131-159. doi:10.2183/pjab.91.131
- Kashfi K. The role of hydrogen sulfide in health and disease. *Biochem Pharmacol*. 2018;149:1-4. doi:10.1016/j.bcp.2018.02.030
- Pan LL, Liu XH, Gong QH, Yang HB, Zhu YZ. Role of cystathionine γ -lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy? *Antioxid Redox Signal*. 2012;17(1):106-118. doi:10.1089/ars.2011.4349
- Renga B. Hydrogen sulfide generation in mammals: the molecular biology of cystathionine- β -synthase (CBS) and cystathionine- γ -lyase (CSE). *Inflamm Allergy Drug Targets*. 2011;10(2):85-91. doi:10.2174/187152811794776286
- Miles EW, Kraus JP. Cystathionine beta-synthase: structure, function, regulation, and location of homocystinuria-causing mutations. *J Biol Chem*. 2004;279(29):29871-29874. doi:10.1074/jbc.R400005200
- Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J Biochem*. 2009;146(5):623-626. doi:10.1093/jb/mvp111
- Tanizawa K. Production of H₂S by 3-mercaptopyruvate sulphurtransferase. *J Biochem*. 2011;149(4):357-359. doi:10.1093/jb/mvr018
- Łowicka E, Bętkowski J. Hydrogen sulfide (H₂S)—the third gas of interest for pharmacologists. *Pharmacol Rep*. 2007;59(1):4-24.
- Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci*. 1996;16(3):1066-1071. doi:10.1523/jneurosci.16-03-01066.1996
- Kamoun P. Endogenous production of hydrogen sulfide in mammals. *Amino Acids*. 2004;26(3):243-254. doi:10.1007/s00726-004-0072-x
- Huang S, Li H, Ge J. A cardioprotective insight of the cystathionine γ -lyase/hydrogen sulfide pathway. *Int J Cardiol Heart Vasc*. 2015;7:51-57. doi:10.1016/j.ijcha.2015.01.010
- Rajendran S, Shen X, Glawe J, Kolluru GK, Kevil CG. Nitric oxide and hydrogen sulfide regulation of ischemic vascular growth and remodeling. *Compr Physiol*. 2019;9(3):1213-1247. doi:10.1002/cphy.c180026
- Yang G, Wu L, Bryan S, Khaper N, Mani S, Wang R. Cystathionine gamma-lyase deficiency and overproliferation of smooth muscle cells. *Cardiovasc Res*. 2010;86(3):487-495. doi:10.1093/cvr/cvp420
- Souza-Paula E, Polonio LCC, Zochio GP, da Silva KP, Kushima H, Dias-Junior CA. Anticontractile effect of perivascular adipose tissue but not of endothelium is enhanced by hydrogen sulfide stimulation in hypertensive pregnant rat aortae. *J Cardiovasc Pharmacol*. 2020;76(6):715-729. doi:10.1097/fjc.0000000000000917
- Liu YH, Lu M, Hu LF, Wong PT, Webb GD, Bian JS. Hydrogen sulfide in the mammalian cardiovascular system. *Antioxid Redox Signal*. 2012;17(1):141-185. doi:10.1089/ars.2011.4005
- Shibuya N, Tanaka M, Yoshida M, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal*. 2009;11(4):703-714. doi:10.1089/ars.2008.2253
- Papapetropoulos A, Pyriochou A, Altaany Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc Natl Acad Sci USA*. 2009;106(51):21972-21977. doi:10.1073/pnas.0908047106
- Saha S, Chakraborty PK, Xiong X, et al. Cystathionine β -synthase regulates endothelial function via protein S-sulphydration. *FASEB J*. 2016;30(1):441-456. doi:10.1096/fj.15-278648
- Mathai JC, Missner A, Kügler P, et al. No facilitator required for membrane transport of hydrogen sulfide. *Proc Natl Acad Sci USA*. 2009;106(39):16633-16638. doi:10.1073/pnas.0902952106
- Kimura H, Shibuya N, Kimura Y. Hydrogen sulfide is a signaling molecule and a cytoprotectant. *Antioxid Redox Signal*. 2012;17(1):45-57. doi:10.1089/ars.2011.4345
- Kanagy NL, Szabo C, Papapetropoulos A. Vascular biology of hydrogen sulfide. *Am J Physiol Cell Physiol*. 2017;312(5):C537-c549. doi:10.1152/ajpcell.00329.2016
- Ciccone V, Genah S, Morbidelli L. Endothelium as a source and target of H(2)S to improve its trophism and function. *Antioxidants (Basel)*. 2021;10(3):486-506. doi:10.3390/antiox10030486
- Mendiola PJ, Naik JS, Gonzalez Bosc LV, Gardiner AS, Birg A, Kanagy NL. Hydrogen sulfide actions in the vasculature. *Compr Physiol*. 2021;11(4):2467-2488. doi:10.1002/cphy.c200036
- Yang G, Wu L, Jiang B, et al. H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science*. 2008;322(5901):587-590. doi:10.1126/science.1162667
- Wang MJ, Cai WJ, Zhu YC. Mechanisms of angiogenesis: role of hydrogen sulphide. *Clin Exp Pharmacol Physiol*. 2010;37(7):764-771. doi:10.1111/j.1440-1681.2010.05371.x
- Köhn C, Dubrovskaya G, Huang Y, Gollasch M. Hydrogen sulfide: potent regulator of vascular tone and stimulator of angiogenesis. *Int J Biomed Sci*. 2012;8(2):81-86.
- Ding Q, Zhu YZ. The cardiovascular effects of hydrogen sulfide: the epigenetic mechanisms. *Adv Exp Med Biol*. 2021;1315:181-203. doi:10.1007/978-981-16-0991-6_8
- Levitt MD, Furne J, Springfield J, Suarez F, DeMaster E. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. *J Clin Invest*. 1999;104(8):1107-1114. doi:10.1172/jci7712

41. Polhemus DJ, Lefer DJ. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. *Circ Res*. 2014;114(4):730-737. doi:[10.1161/circresaha.114.300505](https://doi.org/10.1161/circresaha.114.300505)
42. Bazhanov N, Ansar M, Ivanciuc T, Garofalo RP, Casola A. Hydrogen sulfide: a novel player in airway development, pathophysiology of respiratory diseases, and antiviral defenses. *Am J Respir Cell Mol Biol*. 2017;57(4):403-410. doi:[10.1165/rcmb.2017-0114TR](https://doi.org/10.1165/rcmb.2017-0114TR)
43. Detmar M. Tumor angiogenesis. *J Invest Dermatol Symp Proc*. 2000;5(1):20-23. doi:[10.1046/j.1087-0024.2000.00003.x](https://doi.org/10.1046/j.1087-0024.2000.00003.x)
44. Li S, Xu HX, Wu CT, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. *Angiogenesis*. 2019;22(1):15-36. doi:[10.1007/s10456-018-9645-2](https://doi.org/10.1007/s10456-018-9645-2)
45. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J Natl Cancer Inst*. 2001;93(4):266-276. doi:[10.1093/jnci/93.4.266](https://doi.org/10.1093/jnci/93.4.266)
46. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci USA*. 1995;92(12):5510-5514. doi:[10.1073/pnas.92.12.5510](https://doi.org/10.1073/pnas.92.12.5510)
47. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*. 1999;399(6733):271-275. doi:[10.1038/20459](https://doi.org/10.1038/20459)
48. Salceda S, Caro J. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem*. 1997;272(36):22642-22647. doi:[10.1074/jbc.272.36.22642](https://doi.org/10.1074/jbc.272.36.22642)
49. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. *J Biol Chem*. 1999;274(10):6519-6525. doi:[10.1074/jbc.274.10.6519](https://doi.org/10.1074/jbc.274.10.6519)
50. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. *Trends Biochem Sci*. 2008;33(11):526-534. doi:[10.1016/j.tibs.2008.08.002](https://doi.org/10.1016/j.tibs.2008.08.002)
51. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. *Circ Res*. 1995;77(3):638-643. doi:[10.1161/01.res.77.3.638](https://doi.org/10.1161/01.res.77.3.638)
52. Masoud GN, Li W. HIF-1 α pathway: role, regulation and intervention for cancer therapy. *Acta Pharm Sin B*. 2015;5(5):378-389. doi:[10.1016/j.apsb.2015.05.007](https://doi.org/10.1016/j.apsb.2015.05.007)
53. Ban HS, Uto Y, Nakamura H. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004-2010). *Expert Opin Ther Pat*. 2011;21(2):131-146. doi:[10.1517/13543776.2011.547477](https://doi.org/10.1517/13543776.2011.547477)
54. Semenza G. Signal transduction to hypoxia-inducible factor 1. *Biochem Pharmacol*. 2002;64(5-6):993-998. doi:[10.1016/s0006-2952\(02\)01168-1](https://doi.org/10.1016/s0006-2952(02)01168-1)
55. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. *Cell Growth Differ*. 2001;12(7):363-369.
56. Olson KR, Dombkowski RA, Russell MJ, et al. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol*. 2006;209(Pt 20):4011-4023. doi:[10.1242/jeb.02480](https://doi.org/10.1242/jeb.02480)
57. Wu RS. Hypoxia: from molecular responses to ecosystem responses. *Mar Pollut Bull*. 2002;45(1-12):35-45. doi:[10.1016/s0025-326x\(02\)00061-9](https://doi.org/10.1016/s0025-326x(02)00061-9)
58. Wang M, Guo Z, Wang S. Regulation of cystathionine γ -lyase in mammalian cells by hypoxia. *Biochem Genet*. 2014;52(1-2):29-37. doi:[10.1007/s10528-013-9624-7](https://doi.org/10.1007/s10528-013-9624-7)
59. Fu M, Zhang W, Wu L, Yang G, Li H, Wang R. Hydrogen sulfide (H₂S) metabolism in mitochondria and its regulatory role in energy production. *Proc Natl Acad Sci USA*. 2012;109(8):2943-2948. doi:[10.1073/pnas.1115634109](https://doi.org/10.1073/pnas.1115634109)
60. Teng H, Wu B, Zhao K, Yang G, Wu L, Wang R. Oxygen-sensitive mitochondrial accumulation of cystathionine β -synthase mediated by Lon protease. *Proc Natl Acad Sci USA*. 2013;110(31):12679-12684. doi:[10.1073/pnas.1308487110](https://doi.org/10.1073/pnas.1308487110)
61. Takano N, Peng YJ, Kumar GK, et al. Hypoxia-inducible factors regulate human and rat cystathionine β -synthase gene expression. *Biochem J*. 2014;458(2):203-211. doi:[10.1042/bj20131350](https://doi.org/10.1042/bj20131350)
62. Stein A, Bailey SM. Redox biology of hydrogen sulfide: implications for physiology, pathophysiology, and pharmacology. *Redox Biol*. 2013;1(1):32-39. doi:[10.1016/j.redox.2012.11.006](https://doi.org/10.1016/j.redox.2012.11.006)
63. Olson KR. Hydrogen sulfide as an oxygen sensor. *Antioxid Redox Signal*. 2015;22(5):377-397. doi:[10.1089/ars.2014.5930](https://doi.org/10.1089/ars.2014.5930)
64. Mustafa AK, Gadalla MM, Sen N, et al. H₂S signals through protein S-sulfhydration. *Sci Signal*. 2009;2(96):ra72. doi:[10.1126/scisignal.2000464](https://doi.org/10.1126/scisignal.2000464)
65. Budde MW, Roth MB. Hydrogen sulfide increases hypoxia-inducible factor-1 activity independently of von Hippel-Lindau tumor suppressor-1 in *C. elegans*. *Mol Biol Cell*. 2010;21(1):212-217. doi:[10.1091/mbc.e09-03-0199](https://doi.org/10.1091/mbc.e09-03-0199)
66. Ma DK, Vozdek R, Bhatla N, Horvitz HR. CYSL-1 interacts with the O₂-sensing hydroxylase EGL-9 to promote H₂S-modulated hypoxia-induced behavioral plasticity in *C. elegans*. *Neuron*. 2012;73(5):925-940. doi:[10.1016/j.neuron.2011.12.037](https://doi.org/10.1016/j.neuron.2011.12.037)
67. Flannigan KL, Agbor TA, Motta JP, et al. Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducible factor-1 α . *FASEB J*. 2015;29(4):1591-1602. doi:[10.1096/fj.14-266015](https://doi.org/10.1096/fj.14-266015)
68. Bir SC, Kolluru GK, McCarthy P, et al. Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1 α and vascular endothelial growth factor-dependent angiogenesis. *J Am Heart Assoc*. 2012;1(5):e004093. doi:[10.1161/jaha.112.004093](https://doi.org/10.1161/jaha.112.004093)
69. Liu X, Pan L, Zhuo Y, Gong Q, Rose P, Zhu Y. Hypoxia-inducible factor-1 α is involved in the pro-angiogenic effect of hydrogen sulfide under hypoxic stress. *Biol Pharm Bull*. 2010;33(9):1550-1554. doi:[10.1248/bpb.33.1550](https://doi.org/10.1248/bpb.33.1550)
70. Ling K, Xu A, Chen Y, Chen X, Li Y, Wang W. Protective effect of a hydrogen sulfide donor on balloon injury-induced restenosis via the Nrf2/HIF-1 α signaling pathway. *Int J Mol Med*. 2019;43(3):1299-1310. doi:[10.3892/ijmm.2019.4076](https://doi.org/10.3892/ijmm.2019.4076)
71. Wu B, Teng H, Yang G, Wu L, Wang R. Hydrogen sulfide inhibits the translational expression of hypoxia-inducible factor-1 α . *Br J Pharmacol*. 2012;167(7):1492-1505. doi:[10.1111/j.1476-5381.2012.02113.x](https://doi.org/10.1111/j.1476-5381.2012.02113.x)
72. Wei Z, Shan Y, Tao L, et al. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1 α synthesis, and decreases breast cancer metastasis. *Mol Carcinog*. 2017;56(10):2317-2331. doi:[10.1002/mc.22686](https://doi.org/10.1002/mc.22686)
73. Hellmich MR, Szabo C. Hydrogen sulfide and cancer. *Handb Exp Pharmacol*. 2015;230:233-241. doi:[10.1007/978-3-319-18144-8_12](https://doi.org/10.1007/978-3-319-18144-8_12)
74. Wang RH, Chu YH, Lin KT. The hidden role of hydrogen sulfide metabolism in cancer. *Int J Mol Sci*. 2021;22(12):6562-6577. doi:[10.3390/ijms22126562](https://doi.org/10.3390/ijms22126562)
75. Wang M, Yan J, Cao X, Hua P, Li Z. Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1 α activation. *Biochem Pharmacol*. 2020;172:113775. doi:[10.1016/j.bcp.2019.113775](https://doi.org/10.1016/j.bcp.2019.113775)
76. Zhou Y, Li XH, Zhang CC, et al. Hydrogen sulfide promotes angiogenesis by downregulating miR-640 via the VEGFR2/mTOR pathway. *Am J Physiol Cell Physiol*. 2016;310(4):C305-C317. doi:[10.1152/ajpcell.00230.2015](https://doi.org/10.1152/ajpcell.00230.2015)

77. Sonke E, Verrydt M, Postenka CO, et al. Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential. *Nitric Oxide*. 2015;49:26-39. doi:10.1016/j.niox.2015.06.001
78. Szabo C, Coletta C, Chao C, et al. Tumor-derived hydrogen sulfide, produced by cystathionine- β -synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. *Proc Natl Acad Sci USA*. 2013;110(30):12474-12479. doi:10.1073/pnas.1306241110
79. Guo S, Li J, Huang Z, et al. The CBS-H(2)S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation. *Br J Cancer*. 2022;126(7):1055-1066. doi:10.1038/s41416-021-01681-7
80. Wang L, Shi H, Liu Y, et al. Cystathionine- γ -lyase promotes the metastasis of breast cancer via the VEGF signaling pathway. *Int J Oncol*. 2019;55(2):473-487. doi:10.3892/ijo.2019.4823
81. Tao B, Wang R, Sun C, Zhu Y. 3-Mercaptopyrivate sulfurtransferase, not cystathionine β -synthase nor cystathionine γ -lyase, mediates hypoxia-induced migration of vascular endothelial cells. *Front Pharmacol*. 2017;8:657. doi:10.3389/fphar.2017.00657
82. Pupo E, Pla AF, Avanzato D, et al. Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells. *Free Radic Biol Med*. 2011;51(9):1765-1773. doi:10.1016/j.freeradbiomed.2011.08.007
83. Moccia F, Bertoni G, Pla AF, et al. Hydrogen sulfide regulates intracellular Ca^{2+} concentration in endothelial cells from excised rat aorta. *Curr Pharm Biotechnol*. 2011;12(9):1416-1426. doi:10.2174/138920111798281117
84. Potenza DM, Guerra G, Avanzato D, et al. Hydrogen sulphide triggers VEGF-induced intracellular Ca^{2+} signals in human endothelial cells but not in their immature progenitors. *Cell Calcium*. 2014;56(3):225-234. doi:10.1016/j.ceca.2014.07.010
85. Zhen Y, Pan W, Hu F, et al. Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF- κ B pathway in PLC/PRF/5 hepatoma cells. *Int J Oncol*. 2015;46(5):2194-2204. doi:10.3892/ijo.2015.2914
86. Zhen Y, Zhang W, Liu C, et al. Exogenous hydrogen sulfide promotes C6 glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2 pathways. *Oncol Rep*. 2015;34(5):2413-2422. doi:10.3892/or.2015.4248
87. Lei Y, Zhen Y, Zhang W, et al. Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, angiopoiesis and migration effects via activating HSP90 pathway in EC109 cells. *Oncol Rep*. 2016;35(6):3714-3720. doi:10.3892/or.2016.4734
88. Zhen Y, Wu Q, Ding Y, et al. Exogenous hydrogen sulfide promotes hepatocellular carcinoma cell growth by activating the STAT3-COX-2 signaling pathway. *Oncol Lett*. 2018;15(5):6562-6570. doi:10.3892/ol.2018.8154
89. Lei YY, Feng YF, Zeng B, et al. Exogenous H(2)S promotes cancer progression by activating JAK2/STAT3 signaling pathway in esophageal EC109 cells. *Int J Clin Exp Pathol*. 2018;11(7):3247-3256.
90. Choi KS, Song H, Kim EH, et al. Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: potential mechanisms of gastric cancer prevention by Korean Red Ginseng. *J Ginseng Res*. 2012;36(2):135-145. doi:10.5142/jgr.2012.36.2.135
91. Han H, Wang L, Liu Y, et al. Combination of curcuma zedoary and kelp inhibits growth and metastasis of liver cancer in vivo and in vitro via reducing endogenous H(2)S levels. *Food Funct*. 2019;10(1):224-234. doi:10.1039/c8fo01594e
92. Lu S, Gao Y, Huang X, Wang X. GYY4137, a hydrogen sulfide (H_2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. *Int J Oncol*. 2014;44(4):1259-1267. doi:10.3892/ijo.2014.2305
93. Leskova A, Pardue S, Glawe JD, Kevil CG, Shen X. Role of thiosulfate in hydrogen sulfide-dependent redox signaling in endothelial cells. *Am J Physiol Heart Circ Physiol*. 2017;313(2):H256-h264. doi:10.1152/ajpheart.00723.2016
94. Shukla Y, Arora A, Singh A. Antitumorigenic potential of diallyl sulfide in Ehrlich ascites tumor bearing mice. *Biomed Environ Sci*. 2002;15(1):41-47.
95. Thejass P, Kuttan G. Antiangiogenic activity of diallyl sulfide (DAS). *Int Immunopharmacol*. 2007;7(3):295-305. doi:10.1016/j.intimp.2006.10.011
96. Thejass P, Kuttan G. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by diallyl disulfide (DADS). *Life Sci*. 2007;80(6):515-521. doi:10.1016/j.lfs.2006.09.045
97. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. *Cardiovasc Res*. 2007;76(1):29-40. doi:10.1016/j.cardiores.2007.05.026
98. Puccinelli MT, Stan SD. Dietary bioactive diallyl trisulfide in cancer prevention and treatment. *Int J Mol Sci*. 2017;18(8):1645-1662. doi:10.3390/ijms18081645
99. Almatroodi SA, Alsahli MA, Almatroodi A, Rahmani AH. Garlic and its active compounds: a potential candidate in the prevention of cancer by modulating various cell signalling pathways. *Anticancer Agents Med Chem*. 2019;19(11):1314-1324. doi:10.2174/1871520619666190409100955
100. Powolny AA, Singh SV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. *Cancer Lett*. 2008;269(2):305-314. doi:10.1016/j.canlet.2008.05.027
101. Xiao D, Li M, Herman-Antosiewicz A, et al. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2. *Nutr Cancer*. 2006;55(1):94-107. doi:10.1207/s15327914nc5501_12
102. Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. *Mol Cancer Ther*. 2008;7(8):2328-2338. doi:10.1158/1535-7163.Mct-08-0216
103. Singh SV, Powolny AA, Stan SD, et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. *Cancer Res*. 2008;68(22):9503-9511. doi:10.1158/0008-5472.Can-08-1677
104. Tao Q, Wu C, Xu R, et al. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of glioma cells by inactivating Wnt/ β -catenin signaling. *Cell Tissue Res*. 2017;370(3):379-390. doi:10.1007/s00441-017-2678-9
105. Wu D, Li M, Tian W, et al. Hydrogen sulfide acts as a double-edged sword in human hepatocellular carcinoma cells through EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. *Sci Rep*. 2017;7(1):5134. doi:10.1038/s41598-017-05457-z
106. Yu XH, Cui LB, Wu K, et al. Hydrogen sulfide as a potent cardiovascular protective agent. *Clin Chim Acta*. 2014;437:78-87. doi:10.1016/j.cca.2014.07.012
107. Salloum FN. Hydrogen sulfide and cardioprotection--Mechanistic insights and clinical translatability. *Pharmacol Ther*. 2015;152:11-17. doi:10.1016/j.pharmthera.2015.04.004
108. Hoefer IE. Something is rotten in the state of angiogenesis-- H_2S as gaseous stimulator of angiogenesis. *Cardiovasc Res*. 2007;76(1):1-2. doi:10.1016/j.cardiores.2007.07.010
109. Katsouda A, Bibli SI, Pyriochou A, Szabo C, Papapetropoulos A. Regulation and role of endogenously produced hydrogen sulfide in angiogenesis. *Pharmacol Res*. 2016;113(Pt A):175-185. doi:10.1016/j.phrs.2016.08.026

110. Tao BB, Liu SY, Zhang CC, et al. VEGFR2 functions as an H₂S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. *Antiox Redox Signal*. 2013;19(5):448-464. doi:[10.1089/ars.2012.4565](https://doi.org/10.1089/ars.2012.4565)
111. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis: more vs less. *JAMA*. 2004;292(8):972-977. doi:[10.1001/jama.292.8.972](https://doi.org/10.1001/jama.292.8.972)
112. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. *Antioxid Redox Signal*. 2010;12(9):1065-1077. doi:[10.1089/ars.2009.2945](https://doi.org/10.1089/ars.2009.2945)
113. Kan J, Guo W, Huang C, Bao G, Zhu Y, Zhu YZ. S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3. *Antioxid Redox Signal*. 2014;20(15):2303-2316. doi:[10.1089/ars.2013.5449](https://doi.org/10.1089/ars.2013.5449)
114. Jang H, Oh MY, Kim YJ, et al. Hydrogen sulfide treatment induces angiogenesis after cerebral ischemia. *J Neurosci Res*. 2014;92(11):1520-1528. doi:[10.1002/jnr.23427](https://doi.org/10.1002/jnr.23427)
115. Coletta C, Papapetropoulos A, Erdelyi K, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc Natl Acad Sci USA*. 2012;109(23):9161-9166. doi:[10.1073/pnas.1202916109](https://doi.org/10.1073/pnas.1202916109)
116. Altaany Z, Yang G, Wang R. Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. *J Cell Mol Med*. 2013;17(7):879-888. doi:[10.1111/jcmm.12077](https://doi.org/10.1111/jcmm.12077)
117. Altaany Z, Moccia F, Munaron L, Mancardi D, Wang R. Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide. *Curr Med Chem*. 2014;21(32):3646-3661. doi:[10.2174/0929867321666140706142930](https://doi.org/10.2174/0929867321666140706142930)
118. Nagpure BV, Bian JS. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. *Oxid Med Cell Longev*. 2016;2016:6904327. doi:[10.1155/2016/6904327](https://doi.org/10.1155/2016/6904327)
119. Lo Faro ML, Fox B, Whatmore JL, Winyard PG, Whiteman M. Hydrogen sulfide and nitric oxide interactions in inflammation. *Nitric Oxide*. 2014;41:38-47. doi:[10.1016/j.niox.2014.05.014](https://doi.org/10.1016/j.niox.2014.05.014)
120. Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation—a tale of three gases! *Pharmacol Ther*. 2009;123(3):386-400. doi:[10.1016/j.pharmthera.2009.05.005](https://doi.org/10.1016/j.pharmthera.2009.05.005)
121. Terzuoli E, Monti M, Vellecco V, et al. Characterization of zofenoprilat as an inducer of functional angiogenesis through increased H₂S availability. *Br J Pharmacol*. 2015;172(12):2961-2973. doi:[10.1111/bph.13101](https://doi.org/10.1111/bph.13101)
122. Umaru B, Pyriochou A, Kotsikoris V, Papapetropoulos A, Topouzis S. ATP-sensitive potassium channel activation induces angiogenesis in vitro and in vivo. *J Pharmacol Exp Ther*. 2015;354(1):79-87. doi:[10.1124/jpet.114.222000](https://doi.org/10.1124/jpet.114.222000)
123. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. *Front Biosci*. 2009;14(1):1-18. doi:[10.2741/3228](https://doi.org/10.2741/3228)
124. Bucci M, Papapetropoulos A, Vellecco V, et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler Thromb Vasc Biol*. 2010;30(10):1998-2004. doi:[10.1161/atvbaha.110.209783](https://doi.org/10.1161/atvbaha.110.209783)
125. Bucci M, Papapetropoulos A, Vellecco V, et al. cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. *PLoS One*. 2012;7(12):e53319. doi:[10.1371/journal.pone.0053319](https://doi.org/10.1371/journal.pone.0053319)
126. Bir SC, Xiong Y, Kevil CG, Luo J. Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. *Cardiovasc Res*. 2012;95(1):7-18. doi:[10.1093/cvr/cvs143](https://doi.org/10.1093/cvr/cvs143)
127. Dulak J, Józkowicz A, Dembinska-Kiec A, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 2000;20(3):659-666. doi:[10.1161/01.atv.20.3.659](https://doi.org/10.1161/01.atv.20.3.659)
128. Ziche M, Parenti A, Ledda F, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. *Circ Res*. 1997;80(6):845-852. doi:[10.1161/01.res.80.6.845](https://doi.org/10.1161/01.res.80.6.845)
129. Yuan S, Kevil CG. Nitric oxide and hydrogen sulfide regulation of ischemic vascular remodeling. *Microcirculation*. 2016;23(2):134-145. doi:[10.1111/micc.12248](https://doi.org/10.1111/micc.12248)
130. Hu Q, Wu D, Ma F, et al. Novel Angiogenic Activity And Molecular Mechanisms of ZYZ-803, a slow-releasing hydrogen sulfide-nitric oxide hybrid molecule. *Antioxid Redox Signal*. 2016;25(8):498-514. doi:[10.1089/ars.2015.6607](https://doi.org/10.1089/ars.2015.6607)
131. Das A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD(+)–H(2)S signaling network is a reversible cause of vascular aging. *Cell*. 2018;173(1):74-89.e20. doi:[10.1016/j.cell.2018.02.008](https://doi.org/10.1016/j.cell.2018.02.008)
132. Xiong Y, Chang LL, Tran B, et al. ZYZ-803, a novel hydrogen sulfide-nitric oxide conjugated donor, promotes angiogenesis via cross-talk between STAT3 and CaMKII. *Acta Pharmacol Sin*. 2020;41(2):218-228. doi:[10.1038/s41401-019-0255-3](https://doi.org/10.1038/s41401-019-0255-3)
133. Rushing AM, Donnarumma E, Polhemus DJ, et al. Effects of a novel hydrogen sulfide prodrug in a porcine model of acute limb ischemia. *J Vasc Surg*. 2019;69(6):1924-1935. doi:[10.1016/j.jvs.2018.08.172](https://doi.org/10.1016/j.jvs.2018.08.172)
134. Hayashida R, Kondo K, Morita S, et al. Diallyl trisulfide augments ischemia-induced angiogenesis via an endothelial nitric oxide synthase-dependent mechanism. *Circ J*. 2017;81(6):870-878. doi:[10.1253/circj.CJ-16-1097](https://doi.org/10.1253/circj.CJ-16-1097)
135. Hsieh MH, Tsai HW, Lin KJ, et al. An in situ slow-releasing H(2)S donor depot with long-term therapeutic effects for treating ischemic diseases. *Mater Sci Eng C Mater Biol Appl*. 2019;104:109954. doi:[10.1016/j.msec.2019.109954](https://doi.org/10.1016/j.msec.2019.109954)
136. Donnarumma E, Trivedi RK, Lefer DJ. Protective actions of H₂S in acute myocardial infarction and heart failure. *Compr Physiol*. 2017;7(2):583-602. doi:[10.1002/cphy.c160023](https://doi.org/10.1002/cphy.c160023)
137. Chen Y, Zhang F, Yin J, Wu S, Zhou X. Protective mechanisms of hydrogen sulfide in myocardial ischemia. *J Cell Physiol*. 2020;235(12):9059-9070. doi:[10.1002/jcp.29761](https://doi.org/10.1002/jcp.29761)
138. Lilyanna S, Peh MT, Liew OW, et al. GYY4137 attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to ischemia. *J Mol Cell Cardiol*. 2015;87:27-37. doi:[10.1016/j.yjmcc.2015.07.028](https://doi.org/10.1016/j.yjmcc.2015.07.028)
139. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003;9(6):669-676. doi:[10.1038/nm0603-669](https://doi.org/10.1038/nm0603-669)
140. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. *Nat Rev Mol Cell Biol*. 2006;7(5):359-371. doi:[10.1038/nrm1911](https://doi.org/10.1038/nrm1911)
141. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. *Biochem Biophys Res Commun*. 1992;187(3):1579-1586. doi:[10.1016/0006-291x\(92\)90483-2](https://doi.org/10.1016/0006-291x(92)90483-2)
142. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor- α in cultured human vascular endothelial cells. *J Clin Invest*. 1996;98(2):490-496. doi:[10.1172/jci118816](https://doi.org/10.1172/jci118816)
143. Qipshidze N, Metreveli N, Mishra PK, Lominadze D, Tyagi SC. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. *Int J Biol Sci*. 2012;8(4):430-441. doi:[10.7150/ijbs.3632](https://doi.org/10.7150/ijbs.3632)
144. Nagai Y, Tasaki H, Takatsu H, et al. Homocysteine inhibits angiogenesis in vitro and in vivo. *Biochem Biophys Res Commun*. 2001;281(3):726-731. doi:[10.1006/bbrc.2001.4400](https://doi.org/10.1006/bbrc.2001.4400)
145. Chang PY, Lu SC, Lee CM, et al. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of

- fibroblast growth factor-2 involving G protein and DNA methylation. *Circ Res*. 2008;102(8):933-941. doi:[10.1161/circresaha.108.171082](https://doi.org/10.1161/circresaha.108.171082)
146. Loscalzo J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. *J Clin Invest*. 2009;119(11):3203-3205. doi:[10.1172/jci40924](https://doi.org/10.1172/jci40924)
 147. Majumder A, Singh M, George AK, Behera J, Tyagi N, Tyagi SC. Hydrogen sulfide improves postischemic neoangiogenesis in the hind limb of cystathionine- β -synthase mutant mice via PPAR- γ /VEGF axis. *Physiol Rep*. 2018;6(17):e13858. doi:[10.14814/phy2.13858](https://doi.org/10.14814/phy2.13858)
 148. Jiang W, Liu C, Deng M, et al. H(2)S promotes developmental brain angiogenesis via the NOS/NO pathway in zebrafish. *Stroke Vasc Neurol*. 2021;6(2):244-251. doi:[10.1136/svn-2020-000584](https://doi.org/10.1136/svn-2020-000584)
 149. Lynn EG, Austin RC. Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. *Expert Rev Clin Pharmacol*. 2011;4(1):97-108. doi:[10.1586/ecp.10.130](https://doi.org/10.1586/ecp.10.130)
 150. Mani S, Untereiner A, Wu L, Wang R. Hydrogen sulfide and the pathogenesis of atherosclerosis. *Antioxid Redox Signal*. 2014;20(5):805-817. doi:[10.1089/ars.2013.5324](https://doi.org/10.1089/ars.2013.5324)
 151. van den Born JC, Mencke R, Conroy S, Zeebregts CJ, van Goor H, Hillebrands JL. Cystathionine γ -lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis. *Sci Rep*. 2016;6:34608. doi:[10.1038/srep34608](https://doi.org/10.1038/srep34608)
 152. Sen U, Sathnur PB, Kundu S, et al. Increased endogenous H₂S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. *Am J Physiol Cell Physiol*. 2012;303(1):C41-C51. doi:[10.1152/ajpcell.00398.2011](https://doi.org/10.1152/ajpcell.00398.2011)
 153. Weber GJ, Pushpakumar S, Tyagi SC, Sen U. Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension. *Pharmacol Res*. 2016;113(Pt A):300-312. doi:[10.1016/j.phrs.2016.09.002](https://doi.org/10.1016/j.phrs.2016.09.002)
 154. Qipshidze N, Tyagi N, Sen U, et al. Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice. *Am J Physiol Heart Circ Physiol*. 2010;299(5):H1484-H1493. doi:[10.1152/ajpheart.00577.2010](https://doi.org/10.1152/ajpheart.00577.2010)
 155. Givvimani S, Munjal C, Gargoum R, et al. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. *J Appl Physiol*. 1985;110(4):1093-1100. doi:[10.1152/japplphysiol.01064.2010](https://doi.org/10.1152/japplphysiol.01064.2010)
 156. Polhemus D, Kondo K, Bhushan S, et al. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. *Circ Heart Fail*. 2013;6(5):1077-1086. doi:[10.1161/circheartfailure.113.000299](https://doi.org/10.1161/circheartfailure.113.000299)
 157. Yao M, Lu Y, Shi L, et al. A ROS-responsive, self-immolative and self-reporting hydrogen sulfide donor with multiple biological activities for the treatment of myocardial infarction. *Bioact Mater*. 2022;9:168-182. doi:[10.1016/j.bioactmat.2021.07.011](https://doi.org/10.1016/j.bioactmat.2021.07.011)
 158. van den Born JC, Hammes HP, Greffrath W, van Goor H, Hillebrands JL. Gasotransmitters in vascular complications of diabetes. *Diabetes*. 2016;65(2):331-345. doi:[10.2337/db15-1003](https://doi.org/10.2337/db15-1003)
 159. Liu F, Chen DD, Sun X, et al. Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiopoietin-1 in type 2 diabetes. *Diabetes*. 2014;63(5):1763-1778. doi:[10.2337/db13-0483](https://doi.org/10.2337/db13-0483)
 160. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. *Circulation*. 1998;98(19):2081-2087. doi:[10.1161/01.cir.98.19.2081](https://doi.org/10.1161/01.cir.98.19.2081)
 161. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. *Vasc Endovasc Surg*. 2005;39(4):293-306. doi:[10.1177/153857440503900401](https://doi.org/10.1177/153857440503900401)
 162. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. *J Vasc Surg*. 2007;45:A39-A47. doi:[10.1016/j.jvs.2007.02.068](https://doi.org/10.1016/j.jvs.2007.02.068)
 163. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. *J Clin Invest*. 2007;117(5):1219-1222. doi:[10.1172/jci32169](https://doi.org/10.1172/jci32169)
 164. Chen JX, Stinnett A. Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. *Arterioscler Thromb Vasc Biol*. 2008;28(9):1606-1613. doi:[10.1161/atvbaha.108.169235](https://doi.org/10.1161/atvbaha.108.169235)
 165. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. *Circulation*. 2002;105(3):373-379. doi:[10.1161/hc0302.102143](https://doi.org/10.1161/hc0302.102143)
 166. Wang GG, Li W. Hydrogen sulfide improves vessel formation of the ischemic adductor muscle and wound healing in diabetic db/db mice. *Iran J Basic Med Sci*. 2019;22(10):1192-1197. doi:[10.22038/ijbms.2019.36551.8709](https://doi.org/10.22038/ijbms.2019.36551.8709)
 167. Zhao H, Lu S, Chai J, et al. Hydrogen sulfide improves diabetic wound healing in ob/ob mice via attenuating inflammation. *J Diabetes Complications*. 2017;31(9):1363-1369. doi:[10.1016/j.jdiacomp.2017.06.011](https://doi.org/10.1016/j.jdiacomp.2017.06.011)
 168. Wang G, Li W, Chen Q, Jiang Y, Lu X, Zhao X. Hydrogen sulfide accelerates wound healing in diabetic rats. *Int J Clin Exp Pathol*. 2015;8(5):5097-5104.
 169. Sena CM, Pereira AM, Seica R (2013) Endothelial dysfunction—a major mediator of diabetic vascular disease. *Biochim Biophys Acta*. 1832;12:2216-2231. doi:[10.1016/j.bbadis.2013.08.006](https://doi.org/10.1016/j.bbadis.2013.08.006)
 170. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. *Clin Sci (Lond)*. 2005;109(2):143-159. doi:[10.1042/cs20050025](https://doi.org/10.1042/cs20050025)
 171. Cheng Z, Kishore R. Potential role of hydrogen sulfide in diabetes-impaired angiogenesis and ischemic tissue repair. *Redox Biol*. 2020;37:101704. doi:[10.1016/j.redox.2020.101704](https://doi.org/10.1016/j.redox.2020.101704)
 172. Xue WL, Chen RQ, Zhang QQ, et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. *Am J Physiol Cell Physiol*. 2020;318(5):C857-c869. doi:[10.1152/ajpcell.00406.2019](https://doi.org/10.1152/ajpcell.00406.2019)
 173. Xue W, Zhang Q, Chen Y, Zhu Y. Hydrogen sulfide improves angiogenesis by regulating the transcription of pri-miR-126 in diabetic endothelial cells. *Cells*. 2022;11(17):2651. doi:[10.3390/cells11172651](https://doi.org/10.3390/cells11172651)
 174. Lin F, Yang Y, Wei S, et al. Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway. *Drug Des Devel Ther*. 2020;14:621-633. doi:[10.2147/dddt.S242521](https://doi.org/10.2147/dddt.S242521)
 175. Chen JJY, van der Vlies AJ, Hasegawa U. Hydrogen sulfide-releasing micelles for promoting angiogenesis. *Polym Chem*. 2020;11:4454-4463. doi:[10.1039/d0py00495b](https://doi.org/10.1039/d0py00495b)
 176. Wu F, He Z, Ding R, et al. Danhong promotes angiogenesis in diabetic mice after critical limb ischemia by activation of CSE-H₂S-VEGF axis. *Evid Based Complement Alternat Med*. 2015;2015:276263. doi:[10.1155/2015/276263](https://doi.org/10.1155/2015/276263)
 177. Yang HB, Liu HM, Yan JC, Lu ZY. Effect of diallyl trisulfide on ischemic tissue injury and revascularization in a diabetic mouse model. *J Cardiovasc Pharmacol*. 2018;71(6):367-374. doi:[10.1097/fjc.0000000000000579](https://doi.org/10.1097/fjc.0000000000000579)
 178. Cheng Z, Garikipati VN, Nickoloff E, et al. Restoration of hydrogen sulfide production in diabetic mice improves reparative function of bone marrow cells. *Circulation*. 2016;134(19):1467-1483. doi:[10.1161/circulationaha.116.022967](https://doi.org/10.1161/circulationaha.116.022967)
 179. Coletta C, Módos K, Szczesny B, et al. Regulation of vascular tone, angiogenesis and cellular bioenergetics by the 3-mercaptopyruvate sulfurtransferase/H₂S pathway: functional impairment by

- hyperglycemia and restoration by DL- α -lipoic acid. *Mol Med*. 2015; 21(1):1-14. doi:[10.2119/molmed.2015.00035](https://doi.org/10.2119/molmed.2015.00035)
180. Abdollahi Govar A, Törő G, Szanislo P, et al. 3-Mercaptopyruvate sulfurtransferase supports endothelial cell angiogenesis and bioenergetics. *Br J Pharmacol*. 2020;177(4):866-883. doi:[10.1111/bph.14574](https://doi.org/10.1111/bph.14574)
 181. Smink AM, Najdahmadi A, Alexander M, et al. The effect of a fast-releasing hydrogen sulfide donor on vascularization of subcutaneous scaffolds in immunocompetent and immunocompromised mice. *Biomolecules*. 2020;10(5):722-735. doi:[10.3390/biom10050722](https://doi.org/10.3390/biom10050722)
 182. Lin WC, Huang CC, Lin SJ, et al. In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H(2) S to treat diabetic wounds. *Biomaterials*. 2017;145:1-8. doi:[10.1016/j.biomaterials.2017.08.023](https://doi.org/10.1016/j.biomaterials.2017.08.023)
 183. Das A, Mantena SR, Kannan A, Evans DB, Bagchi MK, Bagchi IC. De novo synthesis of estrogen in pregnant uterus is critical for stromal decidualization and angiogenesis. *Proc Natl Acad Sci USA*. 2009; 106(30):12542-12547. doi:[10.1073/pnas.0901647106](https://doi.org/10.1073/pnas.0901647106)
 184. Bir SC, Kevil CG. Sulfane sustains vascular health: insights into cystathionine γ -lyase function. *Circulation*. 2013;127(25):2472-2474. doi:[10.1161/circulationaha.113.003489](https://doi.org/10.1161/circulationaha.113.003489)
 185. Qi QR, Lechuga TJ, Patel B, et al. Enhanced stromal cell CBS-H₂S production promotes estrogen-stimulated human endometrial angiogenesis. *Endocrinology*. 2020;161(11):176-189. doi:[10.1210/endo/bqaa176](https://doi.org/10.1210/endo/bqaa176)
 186. Hu TX, Wang G, Guo XJ, et al. MiR 20a,-20b and -200c are involved in hydrogen sulfide stimulation of VEGF production in human placental trophoblasts. *Placenta*. 2016;39:101-110. doi:[10.1016/j.placenta.2016.01.019](https://doi.org/10.1016/j.placenta.2016.01.019)
 187. Zhang HH, Chen JC, Sheibani L, Lechuga TJ, Chen DB. Pregnancy augments VEGF-stimulated in vitro angiogenesis and vasodilator (NO and H₂S) production in human uterine artery endothelial cells. *J Clin Endocrinol Metab*. 2017;102(7):2382-2393. doi:[10.1210/jc.2017-00437](https://doi.org/10.1210/jc.2017-00437)
 188. Chen DB, Feng L, Hodges JK, Lechuga TJ, Zhang H. Human trophoblast-derived hydrogen sulfide stimulates placental artery endothelial cell angiogenesis. *Biol Reprod*. 2017;97(3):478-489. doi:[10.1093/biolre/iox105](https://doi.org/10.1093/biolre/iox105)
 189. Wang M, Wang Z, Miao Y, Wei H, Peng J, Zhou Y. Diallyl trisulfide promotes placental angiogenesis by regulating lipid metabolism and alleviating inflammatory responses in obese pregnant mice. *Nutrients*. 2022;14(11):2230. doi:[10.3390/nu14112230](https://doi.org/10.3390/nu14112230)
 190. Tsatsaris V, Goffin F, Foidart JM. Circulating angiogenic factors and preeclampsia. *N Engl J Med*. 2004;350(19):2003-2004. doi:[10.1056/nejm200405063501918](https://doi.org/10.1056/nejm200405063501918)
 191. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. *Am J Obstet Gynecol*. 1998;179(6 Pt 1):1539-1544. doi:[10.1016/s0002-9378\(98\)70021-3](https://doi.org/10.1016/s0002-9378(98)70021-3)
 192. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. *Am J Obstet Gynecol*. 2001;184(6):1267-1272. doi:[10.1067/mob.2001.113129](https://doi.org/10.1067/mob.2001.113129)
 193. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med*. 2006; 355(10):992-1005. doi:[10.1056/NEJMoa055352](https://doi.org/10.1056/NEJMoa055352)
 194. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med*. 2004;350(7):672-683. doi:[10.1056/NEJMoa031884](https://doi.org/10.1056/NEJMoa031884)
 195. Ahmed A, Rezai H, Broadway-Stringer S. Evidence-based revised view of the pathophysiology of preeclampsia. *Adv Exp Med Biol*. 2017;956:355-374. doi:[10.1007/5584_2016_168](https://doi.org/10.1007/5584_2016_168)
 196. Wang K, Ahmad S, Cai M, et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ -lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation*. 2013;127(25):2514-2522. doi:[10.1161/circulationaha.113.001631](https://doi.org/10.1161/circulationaha.113.001631)
 197. di Villa d'E, Bianca R, Fusco F, Mirone V, Cirino G, Sorrentino R. The role of the hydrogen sulfide pathway in male and female urogenital system in health and disease. *Antioxid Redox Signal*. 2017;27(10): 654-668. doi:[10.1089/ars.2017.7079](https://doi.org/10.1089/ars.2017.7079)

How to cite this article: Zhang Y-X, Jing M-R, Cai C-B, et al. Role of hydrogen sulphide in physiological and pathological angiogenesis. *Cell Prolif*. 2023;56(3):e13374. doi:[10.1111/cpr.13374](https://doi.org/10.1111/cpr.13374)